Feb. 13, 2012 A USC research team has pinpointed the source of a genetic disorder that causes life-threatening birth defects, which may allow doctors to quickly diagnose and better treat the disease. The work was published on Feb. 13 in The Journal of Clinical Investigation.
Babies born with the disorder, known as Loeys-Dietz syndrome or Marfan syndrome type II, have cleft palates and other facial characteristics similar to babies born with other diseases -- but they also happen to suffer potentially fatal heart defects, making it critical for them to receive an accurate diagnosis right away.
Researchers from USC found that an abnormally high amount of a protein known as Transforming Growth Factor Beta (TGF-β) outside of cells -- which may be revealed by a blood or tissue test -- in patients with characteristic facial defects is a key indicator of Loeys-Dietz.
"If we can screen patients for this, it can identify Loeys-Dietz syndrome and inform clinical practice," said Yang Chai, director of the USC Center for Craniofacial Molecular Biology and corresponding author of the study. "And perhaps one day we can manipulate the amount [of TGF-β] and possibly rescue the cleft palate before a baby is born. The prospects of this are very promising."
Led by senior postdoctoral fellow Junichi Iwata of the Ostrow School of Dentistry of USC, researchers made their discovery by studying the fetal development of mice. The team found that mutations that affect the way TGF-β communicates outside of a cell may cause Loeys-Dietz syndrome.
TGF-β controls many of the functions within a cell and is known to be heavily involved in the palate's formation -- or failure to form. Typically, it uses a receptor protein known as TGFBR2 to communicate outside of the cell. However, if a mutation causes a roadblock on that communication highway, TGF-β may rely on "surface streets" to get its signal out.
In clinical studies, the activation of this separate signaling pathway resulted in palate and facial defects akin to Loeys-Dietz syndrome. A telltale sign of the alternate pathway's activity is an abnormally high amount of TGF-β outside of the cell.
Moreover, additional genetic defects in the alternate pathway led to a disruption in its signaling, which lowered the amount of TGF-β outside of the cell and rescued the palate and facial deformities -- essentially correcting the defects before birth with no other intervention.
Funding for the research came from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health.
Other social bookmarking and sharing tools:
- Jun-ichi Iwata, Joseph G. Hacia, Akiko Suzuki, Pedro A. Sanchez-Lara, Mark Urata, Yang Chai. Modulation of noncanonical TGF-β signaling prevents cleft palate in Tgfbr2 mutant mice. Journal of Clinical Investigation, 2012; 122 (3): 873 DOI: 10.1172/JCI61498
Note: If no author is given, the source is cited instead.